Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections

Forge Therapeutics, Inc. (Forge) announced that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is being developed to treat hospital-based infections, including those cited on the CDC's most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases. Under the terms of the agreement, Roche has an exclusive option to license the FG-LpxC LUNG program from Forge. Forge will retain control of the program prior to Roche exercising its option, at which time Roche will take over the further development. Forge is eligible to receive up to $190.5M in total payments, including potential sales-based payments and royalties upon commercialization of the program. "Antibiotic-resistance remains an increasing threat to global human health and we are extremely pleased to partner with Roche to accelerate our FG-LpxC LUNG program toward the clinic," said Zachary A. Zimmerman, Ph.D., CEO of Forge. "We look forward to combining our novel approach and innovative chemistry with Roche's proven drug development and commercialization expertise to provide a truly new class of antibiotic for people suffering from serious antibiotic-resistant infections." James Sabry, Head of Roche Pharma Partnering commented, "We are excited to work together with Forge to develop truly innovative antibiotics. This new collaboration demonstrates our strong commitment to combat the urgent global health threat of drug-resistant bacterial infections with novel life-saving treatments that have the potential to make a difference in patients' lives

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!